
Elisabeth Müller
- Researcher; PhD
- +47 99 45 45 71
Cancer immunologist with focus on the response to checkpoint inhibition and resistance mechanisms involving induction of immune suppression. Special interest in the combination of radiation therapy and immunotherapy.
Current projects include characterization of systemic immune responses to checkpoint inhibition in patient samples from clinical trials exploring combination therapy (NIPU, DART, COM-IT-2).
Key competences: spectral flow cytometry analysis of human and mouse samples (PBMCs, tumour and other tissues), cytokine analysis using the Luminex multiplex system, in vivo tumor models in mice, functional in vitro assays
Publications 2024
Blocking S100A9-signaling is detrimental to the initiation of anti-tumor immunity
Front Immunol, 15, 1479502
DOI 10.3389/fimmu.2024.1479502, PubMed 39497822
Publications 2020
The immune microenvironment in typical carcinoid lung tumour, a brief report of four cases
Scand J Immunol, 92 (2), e12893
DOI 10.1111/sji.12893, PubMed 32433774
Publications 2019
Treating osteosarcoma with CAR T cells
Scand J Immunol, 89 (3), e12741
DOI 10.1111/sji.12741, PubMed 30549299
Immune Cell Composition in Human Non-small Cell Lung Cancer
Front Immunol, 9, 3101
DOI 10.3389/fimmu.2018.03101, PubMed 30774636
Publications 2018
Both Type I and Type II Interferons Can Activate Antitumor M1 Macrophages When Combined With TLR Stimulation
Front Immunol, 9, 2520
DOI 10.3389/fimmu.2018.02520, PubMed 30450098
Publications 2017
Generation and Functional In Vitro Analysis of Semliki Forest Virus Vectors Encoding TNF-α and IFN-γ
Front Immunol, 8, 1667
DOI 10.3389/fimmu.2017.01667, PubMed 29276511
Toll-Like Receptor Ligands and Interferon-γ Synergize for Induction of Antitumor M1 Macrophages
Front Immunol, 8, 1383
DOI 10.3389/fimmu.2017.01383, PubMed 29123526
Poly(I:C)-Encapsulating Nanoparticles Enhance Innate Immune Responses to the Tuberculosis Vaccine Bacille Calmette-Guérin (BCG) via Synergistic Activation of Innate Immune Receptors
Mol Pharm, 14 (11), 4098-4112
DOI 10.1021/acs.molpharmaceut.7b00795, PubMed 28974092